Genome & Company (KOSDAQ:314130)

Market Cap	232.50B +146.8%
Revenue (ttm)	24.59B -11.4%
Net Income	-6.43B
EPS	-205.00
Shares Out	36.16M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,025,281
Average Volume	760,270
Open	6,120.00
Previous Close	6,600.00
Day's Range	5,600.00 - 6,630.00
52-Week Range	2,440.00 - 10,180.00
Beta	n/a
RSI	42.50
Earnings Date	n/a

About Genome & Company

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors,...

• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 314130

Financial Performance

In 2025, Genome & Company's revenue was 24.59 billion, a decrease of -11.38% compared to the previous year's 27.74 billion. Losses were -6.43 billion, -68.04% less than in 2024.